CRVS vs. NUKZ
CRVS (Corvus Pharmaceuticals, Inc.) is a stock, while NUKZ (Range Nuclear Renaissance ETF) is Energy Equities fund tracking the Range Nuclear Renaissance Index. Over the past year, CRVS returned 181.37% vs 27.91% for NUKZ. At a 0.34 correlation, their price movements are largely independent.
Performance
CRVS vs. NUKZ - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRVS achieves a 54.94% return, which is significantly higher than NUKZ's 7.57% return.
CRVS
- 1D
- 2.84%
- 1M
- -24.68%
- YTD
- 54.94%
- 6M
- 42.53%
- 1Y
- 181.37%
- 3Y*
- 53.32%
- 5Y*
- 33.63%
- 10Y*
- 0.06%
NUKZ
- 1D
- 1.59%
- 1M
- -5.07%
- YTD
- 7.57%
- 6M
- 4.81%
- 1Y
- 27.91%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
CRVS vs. NUKZ - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
CRVS Corvus Pharmaceuticals, Inc. | 54.94% | 43.93% | 162.25% |
NUKZ Range Nuclear Renaissance ETF | 7.57% | 56.57% | 60.11% |
Correlation
The correlation between CRVS and NUKZ is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Jan 24, 2024 | 0.34 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRVS vs. NUKZ — Risk / Return Rank
CRVS
NUKZ
CRVS vs. NUKZ - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Corvus Pharmaceuticals, Inc. (CRVS) and Range Nuclear Renaissance ETF (NUKZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRVS | NUKZ | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.09 | ||
| Sortino ratioReturn per unit of downside risk | +2.81 | ||
| Omega ratioGain probability vs. loss probability | 1.48 | 1.17 | +0.31 |
| Calmar ratioReturn relative to maximum drawdown | 3.23 | 1.70 | +1.54 |
| Martin ratioReturn relative to average drawdown | 7.03 | 4.11 | +2.92 |
Loading charts...
Drawdowns
CRVS vs. NUKZ - Drawdown Comparison
The maximum CRVS drawdown since its inception was -96.97%, which is greater than NUKZ's maximum drawdown of -33.03%. Use the drawdown chart below to compare losses from any high point for CRVS and NUKZ.
Loading charts...
Drawdown Indicators
| CRVS | NUKZ | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.97% | -33.03% | -63.94% |
Max Drawdown (1Y)Largest decline over 1 year | -56.43% | -16.51% | -39.92% |
Max Drawdown (3Y)Largest decline over 3 years | -70.50% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -92.40% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -96.97% | — | — |
Current DrawdownCurrent decline from peak | -53.25% | -10.39% | -42.86% |
Average DrawdownAverage peak-to-trough decline | -69.28% | -6.06% | -63.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.91% | 6.80% | +19.11% |
Volatility
CRVS vs. NUKZ - Volatility Comparison
Corvus Pharmaceuticals, Inc. (CRVS) has a higher volatility of 23.12% compared to Range Nuclear Renaissance ETF (NUKZ) at 11.24%. This indicates that CRVS's price experiences larger fluctuations and is considered to be riskier than NUKZ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRVS | NUKZ | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.12% | 11.24% | +11.88% |
Volatility (6M)Calculated over the trailing 6-month period | 111.88% | 23.34% | +88.54% |
Volatility (1Y)Calculated over the trailing 1-year period | 180.64% | 30.46% | +150.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 131.02% | 32.94% | +98.08% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 111.13% | 32.94% | +78.19% |
Dividends
CRVS vs. NUKZ - Dividend Comparison
CRVS has not paid dividends to shareholders, while NUKZ's dividend yield for the trailing twelve months is around 0.85%.
| Position | TTM | 2025 | 2024 |
|---|---|---|---|
CRVS Corvus Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% |
NUKZ Range Nuclear Renaissance ETF | 0.85% | 0.91% | 0.09% |
Frequently Asked Questions
CRVS and NUKZ have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRVS has higher volatility (23.12%) compared to NUKZ (11.24%). In terms of maximum drawdown, CRVS dropped -96.97% vs NUKZ's -33.03%.
CRVS currently has the higher Sharpe Ratio (1.01 vs 0.92), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRVS and NUKZ
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer